



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia (Review)

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

*Cochrane Database of Systematic Reviews* 2012, Issue 11. Art. No.: CD008079.

DOI: 10.1002/14651858.CD008079.pub2.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

---

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia (Review)  
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**WILEY**

**DOCKET**  
**ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	4
BACKGROUND . . . . .	6
OBJECTIVES . . . . .	7
METHODS . . . . .	7
RESULTS . . . . .	9
Figure 1. . . . .	11
Figure 2. . . . .	13
Figure 3. . . . .	14
Figure 4. . . . .	16
ADDITIONAL SUMMARY OF FINDINGS . . . . .	21
DISCUSSION . . . . .	24
AUTHORS' CONCLUSIONS . . . . .	26
ACKNOWLEDGEMENTS . . . . .	26
REFERENCES . . . . .	26
CHARACTERISTICS OF STUDIES . . . . .	34
DATA AND ANALYSES . . . . .	68
Analysis 1.1. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 1 OS - overall analysis. . . . .	71
Analysis 1.2. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 2 OS - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	72
Analysis 1.3. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 3 OS - subgrouped by different treatment regimens. . . . .	73
Analysis 1.4. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 4 PFS - overall analysis. . . . .	74
Analysis 1.5. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 5 PFS - subgrouped by age. . . . .	75
Analysis 1.6. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 6 PFS - subgrouped by stage. . . . .	76
Analysis 1.7. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 7 PFS - subgrouped by prognostic factor. . . . .	77
Analysis 1.8. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 8 PFS - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	78
Analysis 1.9. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 9 PFS - subgrouped by different treatment regimens. . . . .	79
Analysis 1.10. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 10 Time to next treatment - overall analysis. . . . .	80
Analysis 1.11. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 11 Time to next treatment - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	81
Analysis 1.12. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 12 ORR - overall analysis. . . . .	82
Analysis 1.13. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 13 ORR - subgrouped by age. . . . .	83
Analysis 1.14. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 14 ORR - subgrouped by stage. . . . .	84

Analysis 1.15. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 15 ORR - subgrouped by prognostic factor. . . . .	85
Analysis 1.16. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 16 ORR - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	86
Analysis 1.17. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 17 ORR - subgrouped by different treatment regimens. . . . .	87
Analysis 1.18. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 18 CRR - overall analysis. . . . .	88
Analysis 1.19. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 19 CRR - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	89
Analysis 1.20. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 20 CRR - subgrouped by different treatment regimens. . . . .	90
Analysis 1.21. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 21 MRD negativity - overall analysis. . . . .	91
Analysis 1.22. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 22 MRD negativity - subgrouped by different treatment regimens. . . . .	92
Analysis 1.23. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 23 Treatment-related mortality - overall analysis. . . . .	93
Analysis 1.24. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 24 Treatment-related mortality - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	94
Analysis 1.25. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 25 Treatment-related mortality - subgrouped by different treatment regimens. . . . .	95
Analysis 1.26. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 26 SAEs - overall analysis. . . . .	96
Analysis 1.27. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 27 SAEs - subgrouped by different treatment regimens. . . . .	97
Analysis 1.28. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 28 Grade 3/4 AEs - overall analysis. . . . .	98
Analysis 1.29. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 29 Grade 3/4 AEs - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	99
Analysis 1.30. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 30 Grade 3/4 AEs - subgrouped by different treatment regimens. . . . .	100
Analysis 1.31. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 31 Anaemia grade 3/4 - overall analysis. . . . .	101
Analysis 1.32. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 32 Anaemia grade 3/4 - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	102
Analysis 1.33. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 33 Neutropenia grade 3/4 - overall analysis. . . . .	103
Analysis 1.34. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 34 Neutropenia grade 3/4 - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	104
Analysis 1.35. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 35 Neutropenia grade 3/4 - subgrouped by different treatment regimens. . . . .	105
Analysis 1.36. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 36 Thrombocytopenia grade 3/4 - overall analysis. . . . .	106

Analysis 1.37. Comparison 1 Anti-leukaemic therapy plus anti-CD20 versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups), Outcome 37 Thrombocytopenia grade 3/4 - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	107
Analysis 2.1. Comparison 2 Anti-leukaemic therapy with anti-CD20 antibody versus anti-leukaemic therapy without anti-CD20 antibody (anti-leukaemic therapy not identical in both groups), Outcome 1 ORR - overall analysis. . . . .	108
Analysis 2.2. Comparison 2 Anti-leukaemic therapy with anti-CD20 antibody versus anti-leukaemic therapy without anti-CD20 antibody (anti-leukaemic therapy not identical in both groups), Outcome 2 ORR - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	109
Analysis 2.3. Comparison 2 Anti-leukaemic therapy with anti-CD20 antibody versus anti-leukaemic therapy without anti-CD20 antibody (anti-leukaemic therapy not identical in both groups), Outcome 3 CRR - overall analysis. . . . .	110
Analysis 2.4. Comparison 2 Anti-leukaemic therapy with anti-CD20 antibody versus anti-leukaemic therapy without anti-CD20 antibody (anti-leukaemic therapy not identical in both groups), Outcome 4 CRR - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	111
Analysis 2.5. Comparison 2 Anti-leukaemic therapy with anti-CD20 antibody versus anti-leukaemic therapy without anti-CD20 antibody (anti-leukaemic therapy not identical in both groups), Outcome 5 Treatment-related mortality. . . . .	112
Analysis 2.6. Comparison 2 Anti-leukaemic therapy with anti-CD20 antibody versus anti-leukaemic therapy without anti-CD20 antibody (anti-leukaemic therapy not identical in both groups), Outcome 6 Treatment-related mortality - subgrouped by different anti-CD20 antibody treatment regimens. . . . .	113
ADDITIONAL TABLES . . . . .	113
APPENDICES . . . . .	116
CONTRIBUTIONS OF AUTHORS . . . . .	119
DECLARATIONS OF INTEREST . . . . .	120
SOURCES OF SUPPORT . . . . .	120
INDEX TERMS . . . . .	120

[Intervention Review]

# Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia

Kathrin Bauer<sup>1</sup>, Michaela Rancea<sup>1</sup>, Verena Roloff<sup>2</sup>, Thomas Elter<sup>3</sup>, Michael Hallek<sup>3</sup>, Andreas Engert<sup>1</sup>, Nicole Skoetz<sup>1</sup>

<sup>1</sup>Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. <sup>2</sup>MRC Biostatistics Unit, Cambridge, UK. <sup>3</sup>Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany

Contact address: Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. [kathrin.bauer@uk-koeln.de](mailto:kathrin.bauer@uk-koeln.de).

**Editorial group:** Cochrane Haematological Malignancies Group.

**Publication status and date:** New, published in Issue 11, 2012.

**Citation:** Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. *Cochrane Database of Systematic Reviews* 2012, Issue 11. Art. No.: CD008079. DOI: 10.1002/14651858.CD008079.pub2.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono- or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impact of these agents remains unclear, as there are hints for increased risk of severe infections.

### Objectives

The objectives of this review are to provide an evidence-based answer regarding the clinical benefits and harms of monoclonal anti-CD20 antibodies (such as rituximab, ofatumumab, GA101) compared to no further therapy or to other anti-leukaemic therapies in patients with CLL, irrespective of disease status.

### Search methods

We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 12, 2011), MEDLINE (from January 1990 to 4 January 2012), and EMBASE (from 1990 to 20 March 2009) as well as conference proceedings (American Society of Hematology, American Society of Clinical Oncology, European Hematology Association and European Society of Medical Oncology) for randomised controlled trials (RCTs).

### Selection criteria

We included RCTs examining monoclonal anti-CD20 antibodies compared to no further therapy or to anti-leukaemic therapy such as chemotherapy or monoclonal antibodies in patients with newly diagnosed or relapsed CLL.

### Data collection and analysis

We used hazard ratios (HR) as effect measures for overall survival (OS), progression-free survival (PFS) and time to next treatment, and risk ratios (RR) for response rates, treatment-related mortality (TRM) and adverse events (AEs). Two review authors independently extracted data and assessed quality of trials.

---

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia (Review) |

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.